Results 191 to 200 of about 40,761 (237)
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Editorial: Unconventional myosins in motile and contractile functions: fifty years on the stage. [PDF]
Front PhysiolTaft MH, Redowicz MJ.
europepmc +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
S2Tag, a novel affinity tag for the capture and immobilization of coiled-coil proteins: Application to the study of human β-cardiac myosin. [PDF]
J Biol ChemBarua B +4 more
europepmc +1 more source
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source
Spindle-localized F-actin regulates polar MTOC organization and the fidelity of meiotic spindle formation. [PDF]
Nat CommunSoto-Moreno EJ +13 more
europepmc +1 more source
Study of the interaction of fish myosin with the products of lipid oxidation: The case of aldehydes
, 2007 C Chopin, M. Koné, Thierry Sérot
openalex +2 more sources
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source